The effect of CYP2C19*17 on platelet aggregation in patients with acute coronary syndrome and percutaneous coronary intervention in Russian population
Proceedings for Annual Meeting of The Japanese Pharmacological Society
The aim of this study was to assess the impact of CYP2C19*17 on low platelet reactivity (PRU<85 for VerifyNow assay) in clopidogrel-treated patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Material and methods A total of 81 (64 males and 17 females) patients with ACS and PCI participated in the study. The mean age of patients enrolled was 63.9±10.9 years. We measured platelet reactivity using VerifyNow P2Y12 assay. Genomic DNA was extracted from venous
... ood. CYP2C19*17 alleles was determined by real-time polymerase chain reaction (Real-Time PCR). Fisher´s exact test was used to assess CYP2C19*17 allele frequency between patient with normal platelets reactivity (PRU>85) and low platelets reactivity (PRU<85). A P-value < 0.05 was considered statistically significant. Results From the 81 patients¸included in research and genotyping by CYP2C19*17¸57(70%) were wild type homozygous (CC), 23 (28%) were heterozygotes (CT) and 1 (2%) was homozygous for the T-allelic variant (TT). C-allele frequency was 84.6% and incidence of T-allele was 15.4%. Genotype frequencies didn´t deviate significantly from Hardy-Weinberg equilibrium (p=0.42¸x2=0.06). There were statistically significant differences in CYP2C19*17 allele frequency between patients with low platelet reactivity (LPR) (PRU<85) and in patients with a normal platelet reactivity (PRU>85): OR, 11.2; 95% CI, 1.18 to 106.32; p=0.0253). Conclusion Carriers of CYP2C19*17 allelic variant have the higher risk of developing LPR and risk of bleeding events¸respectively. Futher research with large data is needed to prove the result of this study.